Clinical trials: Clopidogrel, completed
Coronary Artery Disease, Coronary Artery Stenosis
Nationwide Cohort Study of Antiplatelet Agents as Primary Prevention
There is no specific recommendation regarding pharmacologic treatment as primary prevention for patients with intermediate coronary artery stenosis whose revascularization was deferred based on negative fractional flow reserve…
- Trial name
- NHIS (NCT06281041)
- Testing
- Antiplatelet Agents
- Where
- South Korea
- Volunteers
- 4,657 people
- Sponsor
- Samsung Medical Center
Stable Angina, Unstable Angina
Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - Coronary Intervention With Next Generation Drug-Eluting Stent Platforms and Abbreviated Dual Antiplatelet Therapy (HOST-IDEA) Trial
We had little experience in coronary intervention with recently introduced newer drug-eluting stent (DES) platforms, despite great anticipation, and optimal duration of dual antiplatelet therapy (DAPT) for these stent systems…
- Conditions
- Stable Angina, Unstable Angina, Non-ST Segment Elevation Myocardial Infarction
- Trial name
- HOST-IDEA (NCT02601157)
- Testing
- 3-months DAPT, 1-year DAPT
- Where
- 12 sites in South Korea
- Volunteers
- 2,173 people
- Sponsor
- Seoul National University Hospital
Coronary Artery Disease
PROMUS Element Plus US Post-Approval Study
This study is designed to observe clinical outcomes in patients receiving the PROMUS Element Plus Everolimus-Eluting Platinum Chromium Coronary Stent System in routine clinical practice.
- Trial name
- NCT01589978
- Testing
- PROMUS Element Plus Coronary Stent System, Aspirin, P2Y12 antagonist
- Where
- 52 sites in United States
- Volunteers
- 2,681 people
- Sponsor
- Boston Scientific Corporation
Ischemic Stroke, Patent Foramen Ovale
Patent Foramen Ovale Closure or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence
A patent foramen ovale (PFO) is found more frequently in patients with an ischemic stroke than in control subjects. Therapeutic options to prevent stroke recurrence include antiplatelet drugs, oral anticoagulants, and…
- Conditions
- Ischemic Stroke, Patent Foramen Ovale, Atrial Septal Aneurysm, Migraine
- Trial name
- CLOSE (NCT00562289)
- Testing
- aspirin, Antivitamins K or rivaroxaban or dabigatran or apixaban, Devices for PFO closure
- Where
- France
- Volunteers
- 664 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Coronary Artery Disease, Diabetes Mellitus
Clopidogrel Versus Ticagrelor in Type-2 Diabetes
CLOTILDIA is a single-center, prospective, randomized, open label, cross-over study evaluating the effects of ticagrelor versus high-dose clopidogrel on endothelial function and platelet reactivity in patients with type-2…
- Trial name
- NCT02742987
- Testing
- Ticagrelor, Clopidogrel, Standard medical therapy
- Volunteers
- 42 people
- Sponsor
- Campus Bio-Medico University
Coronary Artery Disease
Simplified Anti-Thrombotic Therapy for FFR
Despite the routine use of procedural anti-coagulation and anti-platelet therapy for FFR calculation, no study has evaluated the optimal anti-thrombotic regimen in patients undergoing FFR.
- Trial name
- SMART-FFR (NCT02384070)
- Testing
- FFR, Aspirin, Clopidogrel
- Volunteers
- 300 people
- Sponsor
- Odessa Heart Institute
Coronary Artery Disease
Clopidogrel High Dose Evaluation for the Patient With Coronary Artery Disease in Japan
The purpose of this study is to evaluate the effect of high dose clopidogrel as the antiplatelet therapy on inhibition of platelet aggregation in Japanese patients scheduled for percutaneous coronary intervention due to ischemic…
- Trial name
- CHOICE (NCT01069302)
- Testing
- Clopidogrel
- Where
- Japan
- Volunteers
- 106 people
- Sponsor
- Takeshi Morimoto
Peptic Ulcer
Efficacy of Proton Pump Inhibitor in Prevention of Clopidogrel-related Peptic Ulcer
Proton Pump Inhibitors (PPI) can prevent the recurrence of peptic ulcer in clopidogrel users.
- Trial name
- NCT01138969
- Testing
- esomeprazole
- Where
- Taiwan
- Volunteers
- 165 people
- Sponsor
- Kaohsiung Veterans General Hospital.
Cervical Artery Dissection, Carotid Artery Dissection
To Determine the Feasibility of a Clinical Trial Comparing Anticoagulants Versus Antiplatelets in the Acute Treatment of Patients With Cervical Artery Dissection
This is a feasibility study to determine if a sufficient number of patients can be recruited throughout the United Kingdom and whether sufficient endpoints can be generated for a full scale therapeutic trial of anticoagulants…
- Conditions
- Cervical Artery Dissection, Carotid Artery Dissection, Vertebral Artery Dissection, Stroke
- Trial name
- CADISS (NCT00238667)
- Testing
- Antiplatelet (Aspirin, Dipyridamole, clopidogrel), Anticoagulant (Unfractionated Heparin, LMW Heparin, Warfarin)
- Where
- United Kingdom
- Volunteers
- 250 people
- Sponsor
- St George's, University of London
Hip Fracture
Hip-Fracture Surgery on Patients in Clopidogrel Therapy
Patients in Clopidogrel therapy alone or in combination with acetylsalicylic acid (Dual Antiplatelet Therapy (DAPT) presenting with a hip-fracture represent the surgeon with the dilemma of putting the patient at risk of a major…
- Trial name
- NCT02391883
- Testing
- Clopidogrel
- Volunteers
- 356 people
- Sponsor
- Hvidovre University Hospital
Heart Defects, Congenital
Efficacy And Safety Of Clopidogrel In Neonates /Infants With Systemic To Pulmonary Artery Shunt Palliation
Contemporary management of cyanotic congenital heart disease includes three stages of surgery. Incidence of shunt thrombosis and death between the two first stages of palliation remains important.
- Trial name
- CLARINET (NCT00396877)
- Testing
- Clopidogrel (SR25990)
- Where
- 31 sites in United States, Argentina and 29 more
- Volunteers
- 906 people
- Sponsor
- Sanofi
Coronary Heart Disease, Percutaneous Coronary Intervention
Comparison of Generic and Original Formulation of Clopidogrel
Clopidogrel is essential for the prevention of vascular events in patients after percutaneous coronary interventions (PCI). Most of our current knowledge with clopidogrel originates from the clinical investigations that had used…
- Trial name
- DOSER-GENERIC (NCT01147133)
- Testing
- Plavix, Kardogrel
- Volunteers
- 75 people
- Sponsor
- University of Pecs
Stable Angina
Atorvastatin and Clopidogrel HIgh DOse in Stable Patients With Residual High Platelet Activity
The purpose of this study is to evaluate if high-dose (80mg/day) atorvastatin might exert an adjunctive anti-platelet effect compared to high-dose clopidogrel (150mg/day) in stable patients with high on-treatment reactivity…
- Trial name
- ACHIDO (NCT01335048)
- Testing
- atorvastatin and clopidogrel, Clopidogrel
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Ospedale Misericordia e Dolce
Heart Defects, Congenital
Long Term Safety of Clopidogrel in Neonates/Infants With Systemic to Pulmonary Artery Shunt Palliation
This study is the extension of the CLARINET study [NCT00396877 -EFC5314] in neonates or infants with cyanotic congenital heart disease palliated with a systemic-to-pulmonary artery shunt.
- Trial name
- CLARINET LT (NCT00833703)
- Testing
- Clopidogrel
- Where
- 15 sites in United States, Brazil and 13 more
- Volunteers
- 49 people
- Sponsor
- Sanofi
Coronary Artery Disease
The Optimal Duration of Dual Antiplatelet Therapy After Implantation of Endeavor Stent
The purpose of this study to determine whether the dual antiplatelet therapy (aspirin and clopidogrel) for 3 months after coronary implantation of zotarolimus-eluting stent is safe in terms of death, myocardial infarction, or…
- Trial name
- DATE (NCT00418860)
- Testing
- Aspirin, Clopidogrel
- Where
- South Korea
- Volunteers
- 1,200 people
- Sponsor
- Samsung Medical Center
Platelet Reactivity
Platelet Function Monitoring in Patients Treated With Clopidogrel at the Time of Primary Percutaneous Coronary Angioplasty
Platelets are a major component of clot formation which can lead to clotting events such as heart attack. During treatment for a heart attack, doctors try to remove this blockage as quickly as possible so that the heart can…
- Trial name
- NCT00827346
- Testing
- Clopidogrel
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Coronary Artery Disease
Safety of High-dose Tirofiban During Coronary Angioplasty
This single-centre study is intended to retrospectively check the safety of high-dose bolus of tirofiban in patients who underwent percutaneous angioplasty.
- Trial name
- SANTISS (NCT00566891)
- Testing
- tirofiban, Clopidogrel
- Where
- Italy
- Volunteers
- 2,000 people
- Sponsor
- S. Anna Hospital
Congenital Heart Defects, Blood Platelet Disorders
Platelet Aggregation Inhibition in Children on Clopidogrel (PICOLO)
PICOLO is a double blind placebo controlled phase II dose ranging, dose escalating study in patients of Blalock-Taussig age categories (neonates and infants/toddlers), to determine the dose providing inhibition of platelet…
- Trial name
- NCT00115375
- Testing
- Clopidogrel (SR25990)
- Where
- 6 sites in United States, Belgium and 4 more
- Volunteers
- 92 people
- Sponsor
- Sanofi
Clopidogrel Non-Responsiveness
The Comparison of Effects Between Increased Dose of Clopidogrel and Addition of Cilostazol
To compare the effect of increased dosing of clopidogrel and adding cilostazol to standard dose of clopidogrel after the insertion of drug-eluting stent in patients with clopidogrel resistance
- Trial name
- 4C-DES (NCT00620646)
- Testing
- aspirin, clopidogrel, aspirin, clopidogrel, cilostazol
- Where
- South Korea
- Volunteers
- 80 people
- Sponsor
- Samsung Medical Center
Acute Myocardial Infarction
Efficacy and Safety of Adding Clopidogrel to Aspirin or Use of Metoprolol in Myocardial Infarction
COMMIT/CCS2 is a large randomised trial of the effects of clopidogrel plus Aspirin versus Aspirin alone in acute heart disease. Patients presenting within 24 hours of the onset of suspected acute MI were potentially eligible…
- Trial name
- NCT00222573
- Testing
- clopidogrel and metoprolol
- Where
- 2 sites in China, United Kingdom
- Volunteers
- 46,000 people
- Sponsor
- University of Oxford